Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Stock analysts at Brookline Capital Markets boosted their FY2026 earnings per share estimates for shares of Monopar Therapeutics in a research note issued to investors on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($2.70) for the year, up from their prior forecast of ($2.88). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.96) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($0.81) EPS.
A number of other equities research analysts also recently weighed in on MNPR. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Barclays reissued an “overweight” rating and set a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a report on Thursday, August 13th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research report on Thursday, July 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Monopar Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.67.
Monopar Therapeutics Price Performance
Shares of MNPR opened at $123.84 on Thursday. The firm has a 50 day simple moving average of $99.68 and a two-hundred day simple moving average of $72.61. Monopar Therapeutics has a one year low of $29.18 and a one year high of $124.82. The company has a market cap of $830.97 million, a P/E ratio of -57.07 and a beta of 1.47.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02.
Institutional Trading of Monopar Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new stake in shares of Monopar Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets lifted its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Monopar Therapeutics in the 4th quarter valued at $65,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Monopar Therapeutics during the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares in the last quarter. Institutional investors own 1.83% of the company’s stock.
About Monopar Therapeutics
Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.
The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.
Featured Stories
- Five stocks we like better than Monopar Therapeutics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
